MK-677 vs Ipamorelin

How to read this comparison

MK-677 and ipamorelin both raise growth hormone by activating the same target — the ghrelin / GH-secretagogue receptor (GHS-R1a). The headline practical difference is delivery: MK-677 (ibutamoren) is an orally-active non-peptide that works as a once-daily tablet, while ipamorelin is an injectable peptide. But the more important difference is how much we actually know about each.

MK-677 is the best-studied compound in this whole class — and that is exactly why it is a cautionary tale. Its biomarker effect is genuinely strong: multiple randomized trials, including a 2-year study in healthy older adults, show it durably raises GH and IGF-1 to youthful levels (Grade B). It also increases fat-free mass — but much of that “lean” gain is body water, and, crucially, the same trials found no improvement in muscle strength or physical function (Grade E). Its Phase III Alzheimer’s trial showed no clinical benefit despite clear target engagement. In other words, MK-677 is the compound that most cleanly demonstrates the central lesson of this class: raising the hormone did not deliver the outcome.

Ipamorelin has the opposite problem — cleaner on paper, but far less known. Its selling point since 1998 has been selectivity: it raises GH while largely sparing cortisol and prolactin. But human data are limited to small pharmacology studies (Grade C for the GH effect), the one rigorous clinical indication it was tested for (post-operative ileus) failed, and every body-composition or anti-aging claim is Grade U — untested in humans.

Safety is where the two genuinely diverge. MK-677’s downsides are documented and not trivial: it consistently increases appetite and fluid retention, and trials found it worsened insulin sensitivity and fasting glucose — a real concern for anyone with or at risk of diabetes — while a frail-elderly program was affected by adverse-event signals including congestive heart failure. Ipamorelin’s short-term side-effect profile looks milder, but that partly reflects how little it has been studied; its long-term safety is simply unknown.

Both are prohibited in sport under WADA’s S2 category (ibutamoren is named explicitly), and neither is approved for human use — MK-677 failed to clear late-stage trials, ipamorelin never got that far. The honest verdict is not that one beats the other. It is that MK-677 has been tested enough to show that raising GH/IGF-1 did not produce the benefits it is marketed for, while ipamorelin has barely been tested at all. This page summarizes the research record; it is not medical advice or an endorsement of use.